Advances in Cancer Immunotherapy™ Live Webcast

When:  Mar 3, 2018 from 08:00 to 14:00 (CT)



Sanjiv S. Agarwala, MD – St. Luke's Cancer Center and Temple University
Rolf A. Brekken, PhD – University of Texas Southwestern Medical Center
Joseph W. Fay, MD – Fay Foundation


Webcast Registration Rates

Program Registration

Online registration for the Advances in Cancer Immunotherapy™ webcast is available until the start of the program at 8 a.m. CT on March 3, 2018.

ACI Post-Program Webinar

As a benefit of attending the ACI program, you have access to participate in two post-program webinars hosted by program organizers. The post-program webinars are another opportunity to ask questions, receive guidance from ACI program organizers, and to stay connected with program attendees. Mark your calendars for the post-program webinar dates:

Program Agenda

Preprogram Course: Introduction to Immunology 

Participation in this online preprogram course is strongly recommended as it contains information that will not be covered at the program on March 3. This interactive course provides foundational knowledge that is necessary for understanding cancer immunotherapy content that will be discussed at the in-person program. Please click HERE to access the course.

March 3, 2018  Program
5.5 AMA PRA Category 1 Credits™ Click here for more detailed CME, CNE and CPE information and program objectives.

Presentations include time for Audience Response System (ARS)-assisted audience interaction as well as general question and answer time.

7 – 8 a.m.

Check-in, Onsite Registration and Networking

Part A: Introduction to Incorporating Immunotherapy Into Clinical Practice

Session I: From Basic Principles to Clinical Applications of Cancer Immunotherapy

8 – 8:05 a.m.

Welcome, Introduction, and Pretest Questions by the Society for Immunotherapy of Cancer

8:05 – 8:35 a.m.

Basic Principles of Cancer Immunotherapy
Joseph Fay, MD – Fay Foundation

8:35 – 8:55 a.m.

Immunotherapy for the Treatment of Melanoma
Jade Homsi, MD – UT Southwestern Medical Center

8:55 – 9:15 a.m.

Immunotherapy for the Treatment of Hematologic Malignancies
Larry Anderson, MD, PhD – UT Southwestern Medical Center

9:15 – 9:35 a.m.

Immunotherapy for the Treatment of Genitourinary Cancers
I. Alex Bowman, MD – UT Southwestern Medical Center

9:35 – 9:55 a.m

Immunotherapy for the Treatment of Lung Cancer
James Kim, MD, PhD – UT Southwestern Medical Center 

9:55 – 10:15 a.m

Immunotherapy for the Treatment of Head and Neck Cancers
Saad A. Khan, MD – UT Southwestern Medical Center

10:15 – 10:25 a.m


Session II: Overcoming Barriers to Incorporating Immunotherapy Into Community Practice

10:25 – 10:30 a.m.

Information About the Society for Immunotherapy of Cancer Resources

10:30 – 11 a.m.

Effective Practices for Incorporating Immunotherapy Into Hospital Operations
Sanjiv S. Agarwala, MD – St. Luke's Cancer Center and Temple University

11 – 11:30 a.m.

Coverage and Reimbursement Challenges and Strategies
Jeff Liticker, RPh, PharmD, BCOP  UT Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center

11:30 – 11:35 a.m.

Take-Home Points for Part A

11:35 a.m. – noon


Part B: Immune-Related Adverse Event (irAE) Management

noon – 12:20 p.m.

Mechanisms of Immune-Related Adverse Events
Rolf A. Brekken, PhD – UT Southwestern Medical Center

12:20 – 12:50 p.m.

Nursing Perspective on irAEs: Patient Education, Monitoring and Management
Michele G. Suter, MSN, FNP-C – McKenney Clinic

12:50 – 1:20 p.m.

Management and Mitigation of irAEs for Immunotherapy Prescribers
Saad A. Khan, MD – UT Southwestern Medical Center

1:20 – 1:50 p.m.

Identification and Management of Immune-Related Adverse Events in the Emergency Setting
Robert Suter, DO, FAAEM – UT Southwestern Medical Center

1:50 – 1:55 p.m.

Posttest Questions by the Society for Immunotherapy of Cancer

1:55 – 2 p.m.

Take-Home Points for Part B and Closing Remarks

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE- and CNE-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, these six-hour programs will facilitate understanding of:

  • The rationale for common approaches to immunotherapy
  • The clinical applications of immunotherapy for disease states with FDA-approved treatments (melanoma, and lung, genitourinary, hematologic, and head and neck cancers)
  • Operational and reimbursement barriers to implementing immunotherapy in a community setting and strategies to overcome them
  • The identification and management of immune-related adverse events from the nursing and prescriber perspective in the clinic and emergency settings

Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field through two post-program webinars and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice. 

For more information, including program objectives, click here.

This program is presented in collaboration with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC).       



The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants
from Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Incyte Corporation, Merck & Co., Inc. and Prometheus Laboratories Inc.

#Adverse Events